ArticleAvicenna journal of phytomedicine2026
Antioxidant efficacy of
Article in Avicenna journal of phytomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated the hepatoprotective effects of Materials and Methods: Fifty neonatal Wistar rats (2 weeks old) were divided into five groups (n=10): a control group, a PHZ-only group, and three PHZ-treated groups receiving CNE (1, 2.5, and 5 mg/kg, orally, thrice daily for 10 days). PHZ was used to induce hemolysis and hyperbilirubinemia. Markers of liver function, oxidative stress, and antioxidant capacity were analyzed, alongside β-glucuronidase activity. Results: CNE significantly mitigated PHZ-induced hyperbilirubinemia by reducing serum bilirubin levels and dose-dependently decreasing oxidative stress markers, including reactive oxygene species ROS, malondialdehyde (MDA), and protein carbonylation. It also restored glutathione (GSH) levels and total antioxidant capacity. The highest CNE dose (5 mg/kg) demonstrated the most pronounced effects. Furthermore, CNE inhibited β-glucuronidase activity, contributing to its hepatoprotective action. Hierarchical clustering and heatmap analyses corroborated the dose-dependent antioxidant and hepatoprotective properties of CNE. Conclusion: These findings highlight the hepatoprotective potential of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.